Loading data for SPRY — first visit, this takes a few seconds.
ARS Pharmaceuticals, Inc.
4.76 -0.30 (-5.93%)
4.64 +3.11%
- Market Cap
- $447.5M
- Volume
- 2.57M
- Dividend yield
- n/a
- Next earnings date
- Nov 10, 2026
ARS Pharmaceuticals, Inc. (SPRY) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $22.68M | n/a | +184.47% |
| EPS | -$0.63 | -$0.14 | -36.96% |
Metrics
- Bid
- 3.89
- Market Cap
- 448M
- Revenue (ttm)
- 117M
- Net Income (ttm)
- -215M
- 1.00
- -2.18
- n/a
- -5.02
- P/B (ttm)
- 35.71
- P/S (ttm)
- 3.83
- Earnings Date
- Nov 10, 2026
- Ask
- 6.72
- Volume
- 2,570,805
- Avg. Volume (20D)
- 1,998,462
- Open
- 5.13
- Previous Close
- 5.06
- Day's Range
- 4.73 - 5.18
- 52-Week Range
- 4.73 - 13.15
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About ARS Pharmaceuticals, Inc.
View profile →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 195
Stock Exchange NasdaqGM
Ticker Symbol SPRY
Website https://ars-pharma.com